Intrinsiqs

Is Alnylam Pharmaceuticals, Inc. overvalued?

Alnylam Pharmaceuticals, Inc. (ALNY) — key valuation metrics and fundamentals.

No verdict
Price
$255.96
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$34.25B
Dividend yield
0.0%
Return on equity
93.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares ALNY's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.